PENTAGASTRIN STIMULATED CALCITONIN TESTING IN MTC AND MEN 2

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定是研究者机构。本方案旨在为ret原癌基因阳性患者（多发性内分泌肿瘤2A或2B家族成员）提供系统性随访（五肽胃泌素刺激的降钙素水平），这些患者接受了甲状腺切除术。这些包括接受预防性甲状腺切除术的年轻患者（例如，根据可证实的甲状腺髓样癌发生前的危险基因型进行甲状腺切除术）。因此，研究问题涉及预防性甲状腺切除术在预防遗传性甲状腺髓样癌中的有效性，以及侵袭性甲状腺切除术在治疗家族性甲状腺髓样癌中的有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol is designed to provide systematic follow-up (with pentagastrin-stimulated calcitonin levels) of ret proto-oncogene positive patients who are members of Multiple Endocrine Neoplasia 2A or 2B families and who have undergone thyroidectomy. These include young patients who have undergone prophylactic thyroidectomy (e.g., thyroidectomy based on the at-risk genotype before the development of demonstrable medullary thyroid carcinoma) as those treated surgically for medullary thyroid carcinoma. Thus, the research questions relate to the efficacy of prophylactic thyroidectomy in the prevention of medullary thyroid carcinoma in genetically at-risk individuals and the efficacy of aggressive thyroidectomy in the treatment of familial medullary thyroid carcinoma.